SEC Tracker
Get the app

Compass Therapeutics CMPX

Compass Therapeutics Q1 FY24: net loss $10.8M

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Compass Therapeutics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$10.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Cash and cash equivalents$23.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  3. Cash from operations−$13.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Compass Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Ocugen OCGN public float $279M, Jun 30, 2025
  2. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Standard Biotools LAB public float $291M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.